• Je něco špatně v tomto záznamu ?

Stanovení stavu estrogenních receptorů a stavu ERBB2 u karcinomu prsu: studie profilování genové exprese
[Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study]

Yun Gong, Kai Yan, Feng Lin, Keith Anderson, Christos Sotiriou, Fabrice Andre, Frankie A. Holmes, Vicente Valero, Daniel Booser, John E. Pippen Jr, Svetislava Vukelja, Henry Gomez, Jaime Mejia, Luis J. Barajas, Kenneth R. Hess, Nour...

. 2007 ; 6 (3) : 233-241.

Jazyk čeština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc07512778

Gene expression microarrays are being used to develop new prognostic and predictive tests for breast cancer, and might be used at the same time to confirm oestrogen-receptor status and ERBB2 status. Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling. METHODS: We used gene expression data of 495 breast cancer samples to assess the correlation between oestrogen receptor (ESR1) and ERBB2 mRNA and clinical status of these genes (as established by immunohistochemical [IHC] or fluorescence in-situ hybridisation [FISH], or both). Data from 195 fine-needle aspiration (FNA) samples were used to define mRNA cutoff values that assign receptor status. We assessed the accuracy of these cutoffs in two independent datasets: 123 FNA samples and 177 tissue samples (ie, resected or core-needle biopsied tissues). Profiling was done at two institutions by use of the same platform (Affymetrix U133A GeneChip). All data were uniformly normalised with dCHIP software. FINDINGS: ESR1 and ERBB2 mRNA levels correlated closely with routine measurements for receptor status in all three datasets. Spearman's correlation coefficients ranged from 0.62 to 0.77. An ESR1 mRNA cutoff value of 500 identified oestrogen-receptor-positive status with an overall accuracy of 90% (training set), 88% (first validation set), and 96% (second validation set). An ERBB2 mRNA threshold of 1150 identified ERBB2-positive status with the overall accuracy of 93% (training set), 89% (first validation set), and 90% (second validation set). Reproducibility of mRNA measurements in 34 replicate experiments was high (correlation coefficient 0.975 for ESR1, 0.984 for ERBB2). INTERPRETATION: Amounts of ESR1 and ERBB2 mRNA as measured by the Affymetrix GeneChip reliably and reproducibly establish oestrogen-receptor status and ERBB2 status, respectively.

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study

Bibliografie atd.

Lit.: 36

000      
00000naa 2200000 a 4500
001      
bmc07512778
003      
CZ-PrNML
005      
20111210124438.0
008      
081121s2007 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Gong, Yun
245    10
$a Stanovení stavu estrogenních receptorů a stavu ERBB2 u karcinomu prsu: studie profilování genové exprese / $c Yun Gong, Kai Yan, Feng Lin, Keith Anderson, Christos Sotiriou, Fabrice Andre, Frankie A. Holmes, Vicente Valero, Daniel Booser, John E. Pippen Jr, Svetislava Vukelja, Henry Gomez, Jaime Mejia, Luis J. Barajas, Kenneth R. Hess, Nour Sneige,Gabriel N. Hortobagyi, Lajos Pusztai, W. Frase Symmans ; Daria Kučová
246    11
$a Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
314    __
$a Department of Pathology, University of Texas MD Anderson Cancer Center, Houston
504    __
$a Lit.: 36
520    9_
$a Gene expression microarrays are being used to develop new prognostic and predictive tests for breast cancer, and might be used at the same time to confirm oestrogen-receptor status and ERBB2 status. Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling. METHODS: We used gene expression data of 495 breast cancer samples to assess the correlation between oestrogen receptor (ESR1) and ERBB2 mRNA and clinical status of these genes (as established by immunohistochemical [IHC] or fluorescence in-situ hybridisation [FISH], or both). Data from 195 fine-needle aspiration (FNA) samples were used to define mRNA cutoff values that assign receptor status. We assessed the accuracy of these cutoffs in two independent datasets: 123 FNA samples and 177 tissue samples (ie, resected or core-needle biopsied tissues). Profiling was done at two institutions by use of the same platform (Affymetrix U133A GeneChip). All data were uniformly normalised with dCHIP software. FINDINGS: ESR1 and ERBB2 mRNA levels correlated closely with routine measurements for receptor status in all three datasets. Spearman's correlation coefficients ranged from 0.62 to 0.77. An ESR1 mRNA cutoff value of 500 identified oestrogen-receptor-positive status with an overall accuracy of 90% (training set), 88% (first validation set), and 96% (second validation set). An ERBB2 mRNA threshold of 1150 identified ERBB2-positive status with the overall accuracy of 93% (training set), 89% (first validation set), and 90% (second validation set). Reproducibility of mRNA measurements in 34 replicate experiments was high (correlation coefficient 0.975 for ESR1, 0.984 for ERBB2). INTERPRETATION: Amounts of ESR1 and ERBB2 mRNA as measured by the Affymetrix GeneChip reliably and reproducibly establish oestrogen-receptor status and ERBB2 status, respectively.
650    _2
$a nádory prsu $x genetika $7 D001943
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a geny erbB-2 $x genetika $7 D018734
650    _2
$a lidé $7 D006801
650    _2
$a messenger RNA $x analýza $7 D012333
650    _2
$a receptory pro estrogeny $x biosyntéza $x genetika $7 D011960
700    1_
$a Yan, Kai
700    1_
$a Lin, Feng
700    1_
$a Anderson, Keith $7 gn_A_00006156
700    1_
$a Sotiriou, Christos
700    1_
$a Andre, Fabrice $7 gn_A_00006354
700    1_
$a Holmes, Frankie A.
700    1_
$a Valero, Vicente
700    1_
$a Booser, Daniel
700    1_
$a Pippen, John E.
700    1_
$a Vukelja, Svetislava
700    1_
$a Gomez, Henry
700    1_
$a Mejia, Jaime
700    1_
$a Barajas, Luis J.
700    1_
$a Kučová, Daria, $d 1959- $7 ola2004235604
773    0_
$w MED00012637 $t The lancet oncology CZ $g Roč. 6, č. 3 (2007), s. 233-241 $x 1213-9432
910    __
$a ABA008 $b B 2277 $c 1153 b $y 1
990    __
$a 20081118143934 $b ABA008
991    __
$a 20081128093022 $b ABA008
999    __
$a ok $b bmc $g 628372 $s 480819
BAS    __
$a 3
BMC    __
$a 2007 $b 6 $c 3 $d 233-241 $i 1213-9432 $m The lancet oncology CZ $x MED00012637
LZP    __
$a 2008-20/mkme

Najít záznam

Citační ukazatele

Možnosti archivace